6 results about "Scid mice" patented technology

This invention provides an irinotecan-conjugated polypeptide compound, its preparation method, and its application, belonging to the field of biomedical technology. Irinotecan (Dxd) is the active pharmaceutical ingredient. Irinotecan belongs to the topoisomerase I inhibitor class—camptothecin derivatives—and is a semi-synthetic small molecule chemotherapeutic drug capable of directly killing cancer cells in the active division phase and inhibiting tumor growth. TYLCTACDYTHH is a highly effective PDPN-targeting peptide that can effectively target the PDPN site in human glioblastoma. In vitro and in vivo experimental results show that the conjugated compound of this invention can significantly inhibit the proliferation of primary glioblastoma cells and effectively inhibit the growth of intracranial orthotopic xenografts in NOD-SCID mice, demonstrating good anti-tumor activity. This compound shows promise for targeted therapy of glioblastoma and has the potential to prolong patient survival.

This invention relates to the field of biomedical technology, and in particular to the application of hD1R protein in the preparation of drugs for the treatment of AML. Addressing the current lack of systematic and in-depth research on whether hD1R protein can directly act on AML cells and whether it has a synergistic effect with existing standard chemotherapy drugs (such as anthracyclines), this invention, through a series of in vivo and in vitro experiments and the construction of a NOD / SCID mouse transplantation model, confirms that hD1R protein alone can effectively inhibit AML cell proliferation, induce apoptosis, inhibit AML cell colony formation, and downregulate the expression of the key anti-apoptotic gene Bcl2 in AML cells. It also confirms that hD1R treatment can significantly prolong the survival of model mice. Furthermore, by setting up a Dox+hD1R group (combined experimental group), it is confirmed that when hD1R protein is used in combination with anthracycline chemotherapy drugs, it exhibits significant synergistic effects in inhibiting AML cell proliferation, promoting AML cell apoptosis, downregulating the expression of the anti-apoptotic gene Bcl2 in AML cells, and inhibiting AML cell colony formation.

The invention discloses a GBM animal model and a construction method and application thereof, and belongs to the technical field of animal model construction. A construction method of a GBM mouse model comprises the following steps that S1, a mouse is anesthetized, the respiratory rate of the mouse is adjusted, and after prepared skin is disinfected, the mouse is cut backwards from the midpoint of a connecting line of inner-eye canthi along a median sagittal line; s2, drilling, injecting a cell suspension, retaining a needle for a certain time, slowly pulling out the needle, and plugging a needle hole; s3, performing disinfection after surgical incision suturing, performing conventional feeding, and checking whether modeling succeeds or not. U87 cells of a female NOD SCID mouse of 8 weeks old are adopted as immune cells, the GBM mouse model is successfully constructed through a specific injection method at a specific position, a specific depth and a specific injection method on the head of the mouse, the GBM of the model mouse is heterogeneous GBM, and the model is stable and reliable and can be used for GBM research and new drug curative effect test; the method provided by the invention is high in success rate of constructing the heterogeneity GBM mouse model, and is simple and easy to operate.

The present invention provides the use of a FoXO1 inhibitor in the preparation of a drug for the prevention and treatment of lymphoma. The present invention selected AS1842856 for experiments in a NOD SCID mouse lymphoma tumor model. Administration via intraperitoneal injection effectively prevented and treated the occurrence of PEL (Pelvic Encephalopathy). Dissection of the mice revealed no symptoms of the drug affecting any of the mouse's internal organs. When AS1842856 was used to directly inhibit FoXO1 and FoXO3 in latently KSHV-infected lymphoma cells, it was found that the cells' antioxidant capacity was weakened, thereby increasing intracellular ROS levels, leading to KSHV reactivation and ultimately massive PEL cell death. Inducing oncolytic reactivation of endogenous viruses from latently infected tumor cells is a very attractive cancer treatment option, and inhibitors of FoXOs will have promising application prospects in the prevention and treatment of lymphoma.

The present invention discloses a method for inducing colitis by cell-acquired transfer, which relates to the field of biomedicine technology. The method for inducing colitis by cell-acquired transfer comprises the following steps: S1, replicating a colitis model; S2, enriching mTh17 cells by flow cytometry; S3, inducing colitis by mTh17 cell-acquired transfer; S4, collecting colitis samples; S5, assessing the disease activity index; S6, processing pathological tissues: 1. paraffin sectioning; 2. hematoxylin-eosin staining. By using the method for inducing colitis by cell-acquired transfer provided in the present application, memory Th17 cells with high expression of IL-17A are obtained in vitro; mTh17 cells are acquired and transferred to SCID mice to successfully induce colitis. This helps to analyze the mechanism of action of mTh17 cells in the pathogenesis of UC, can be used to evaluate the efficacy of new anti-UC drugs, and promote the development of new anti-UC drugs.

The invention belongs to the technical field of medicines, discloses application of a compound CA3 in inhibiting leukemia cell proliferation and treating leukemia, and particularly discloses application of the compound CA3 shown as a formula (I) in treating leukemia. Pharmacological experiments prove that the CA3 can obviously inhibit the proliferation of leukemia cells HL-60 (the IC50 value is 5.4 * 10 <-7 > M); the tumor volume of an HL-60 cell ectopic transplantation NOD-SCID mouse is reduced 11 days after the CA3 is administered, and the tumor weight of the HL-60 cell ectopic transplantation NOD-SCID mouse is reduced 14 days after the CA3 is administered. Experimental results show that the CA3 significantly inhibits leukemia cell proliferation at a cellular level and significantly reduces leukemia tumor growth at an animal level.